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Protein kinases are known primarily for their ability to phosphorylate protein substrates, which constitutes an
essential biological process. Recently, compelling evidence has accumulated that the functions of many pro-
tein kinases extend beyond phosphorylation and include an impressive spectrum of non-catalytic roles, such
as scaffolding, allosteric regulation, or even protein-DNA interactions. How the conserved kinase fold shared
by all metazoan protein kinases can accomplish these diverse tasks in a specific and regulated manner is
poorly understood. In this review, we analyze the molecular mechanisms supporting phosphorylation-inde-
pendent signaling by kinases and attempt to identify common and unique structural characteristics that
enable kinases to perform non-catalytic functions. We also discuss how post-translational modifications,
protein-protein interactions, and small molecules modulate these non-canonical kinase functions. Finally,
we highlight current efforts in the targeted design of small-molecule modulators of non-catalytic kinase func-
tions, a new pharmacological challenge for which structural considerations are more important than ever.Introduction
By catalyzing phosphorylation, protein kinases play a central role
in regulating cellular homeostasis. This enzymatic function is
mediated by the conserved kinase domain fold, which is highly
preserved among all protein kinases. Despite their structural
conservation, protein kinases exhibit remarkable diversity in their
ability to recognize unique sets of substrates, as well as other
binding partners that might serve as activators or inhibitors.
The specificity of these interactions is often encoded in unique
binding sites within the kinase domain itself. A kinase domain
therefore skillfully couples its role as a catalytic enzyme with a
role as a protein scaffold to orchestrate an efficient and specific
phosphotransfer.
Studies over the past decades have revealed that scaffolding
functions of kinases extend beyond a mere supporting role in
phosphorylation. This was initially suggested by observations
that inhibition of kinase function can result in fundamentally
different biological outputs depending on the experimental
approach used to inhibit the enzyme. For example, genetic
knockout of the epidermal growth factor receptor (EGFR) results
in animal death soon after birth (Miettinen et al., 1995), while loss
of EGFR activity through a ‘‘kinase-dead’’ V743G mutation pro-
duces only mild epithelial defects (Luetteke et al., 1994). Simi-
larly, there are significant phenotypic discrepancies between
manifestations of Parkinson’s disease observed in mice in which
leucine-rich repeat kinase 2 (LRRK2) is knocked out versus inac-
tivated by a D1994S (D166 in protein kinase A [PKA]) mutation
(Herzig et al., 2011). Although these discrepancies might be
partially attributed to the fact that mutations or inhibitor treat-
ment, as opposed to gene knockdown, might still preserve a
low level of kinase activity, they also suggest an alternative,
more exciting possibility that the functions of kinases are not
limited to catalyzing phosphorylation but extend to other
roles that are independent of enzymatic activity. These divergentStroutcomes of kinase inactivation have been found for an
increasing number of kinases, indicating that the roles of kinases
in cellular signaling are considerably more complex than previ-
ously thought (Figure 1 and Table 1).
The potential of the kinase domain fold to signal through an
alternative non-catalytic mechanism is perhaps best exemplified
by a subset of protein kinases that have seemingly evolved to
lack catalytic activity and have thus been termed ‘‘pseu-
dokinases.’’ Pseudokinases are defined by the presence of mu-
tations in critical catalytic residues that prevent catalysis of
phosphorylation while preserving the overall structure of the ki-
nase domain (Manning et al., 2002). Although initially thought
of as evolutionary remnants that lack biological function, pseu-
dokinases are often highly conserved in evolution and play
essential roles in signaling. As such, pseudokinases represent
10% of all human kinases (Figure 1), underscoring the impor-
tance of the non-catalytic utility of the kinase scaffold for cellular
signaling. They also provide elegant case studies with which to
investigate the molecular basis for non-catalytic kinase func-
tions, since these functions have likely evolved in pseudokinases
in isolation from the constraints that catalysis imposes on the
structure of the kinase domain.
With our increasing appreciation for the phosphorylation-inde-
pendent roles of kinases in cellular signaling, several important
questions emerge. First, what are the structural components
within the kinase domain that mediate these non-catalytic func-
tions, and what are the molecular mechanisms of their regula-
tion? Second, can we modulate the non-catalytic functions of
kinases using small molecules in a manner analogous to the
ways in which their catalytic activity can be regulated? Lastly,
and perhaps most critical from a therapeutic standpoint, how
do existing inhibitors of kinase catalytic functions affect kinase
non-catalytic functions? In this review, we analyze the molecular
mechanisms supporting phosphorylation-independent signalingucture 24, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 7
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Figure 1. Kinases Reported to Have Non-
catalytic Functions
Active kinases (red circles) and pseudokinases
(blue circles) that have been reported to perform
non-catalytic functions are marked on the human
kinome tree. The names of kinases whose crystal
structures are available are underlined. Illustration
reproduced courtesy of Cell Signaling Technology,
Inc. (www.cellsignal.com).
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Reviewin kinases and attempt to identify common structural character-
istics that enable kinases to perform these non-catalytic func-
tions. We then discuss how these non-canonical functions could
be modulated using small molecules, and examine current prog-
ress toward the development of compounds that modulate non-
enzymatic activities of kinases.
Known Non-catalytic Functions of Kinases
Kinases interact with a surprisingly wide range of binding part-
ners given the high degree of conservation of the kinase domain
fold. This versatility enables kinases to perform a diverse array of
non-catalytic functions, including allosterically regulating other
kinases and/or unrelated enzymes, acting asmolecular scaffolds
to coordinate interactions between different components of
signaling pathways, and regulating transcription through interac-
tions with transcription factors or by binding directly to DNA.
Structural and functional studies in recent years have shown
that each of these novel kinase functions utilizes a uniquemolec-
ular mechanism, highlighting an impressive degree of ada-
ptation.8 Structure 24, January 5, 2016 ª2016 Elsevier Ltd All rights reservedAllosteric Regulation of Other
Kinases
Several kinases and pseudokinases allo-
sterically regulate the catalytic activity
of other kinases through dimerization
(Figure 2A). The human epidermal growth
factor receptor (HER/EGFR) family of re-
ceptor tyrosine kinases is one example of
such regulation. The HER family consists
of three catalytically active kinases,
EGFR, HER2, and HER4, and one catalyt-
ically impaired pseudokinase, HER3.
Although HER3 retains very weak kinase
activity in vitro (Shi et al., 2010), thisactivity
does not seem to be necessary for HER3
signaling (Mendrola et al., 2013). The ca-
nonical model of receptor tyrosine kinase
activation postulates that transphosphor-
ylation of kinases in response to ligand-
induced receptor dimerization is neces-
sary for kinase activation and, therefore,
is contingent on both receptors being
catalytically active. However, the catalyti-
cally active HER receptors (EGFR, HER2,
and HER4) readily form signaling-compe-
tent heterodimeric complexes with the
catalytically impaired HER3, suggesting
that only one kinase in HER receptor di-mers needs to be catalytically active. Comparisons of crystal
structuresof theEGFRkinasedomain in inactiveandactive states
revealed that, instead of transphosphorylation, EGFR activation
reliesonasymmetricdimerizationbetweenkinasedomainswhere
one kinase allosterically activates the other (Brewer et al., 2009;
Jura et al., 2009a; Zhang et al., 2006). This allosteric activator
function is independent of kinase catalytic activity but reliant
upon the structure of the kinase domain (Zhang et al., 2006).
Consequently, it can be carried out by both the catalytically active
and catalytically impaired HER kinases, enabling HER3 to form
functional signaling complexes with other HER receptors (Jura
et al., 2009b; Littlefield et al., 2014; Monsey et al., 2010).
The RAF family of kinases (A-RAF, B-RAF, and C-RAF) also re-
lies on catalysis-independent allosteric activation between two
kinase domains, yet through a very different mechanism. Anal-
ysis of RAF mutations found in human cancers has identified
several substitutions in B-RAF (G466E, G466V, G596R) that
impair its catalytic activity but still stimulate cell proliferation by
activating C-RAF through heterodimerization (Garnett et al.,
2005; Wan et al., 2004). In addition, under subsaturating
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mitogen-activated protein kinase (MAPK) signaling in cells by
promoting dimerization of inhibited B-RAF molecules with unin-
hibited B-RAF and C-RAF (Hatzivassiliou et al., 2010; Heidorn
et al., 2010; Poulikakos et al., 2010). These observations have
revealed that RAF kinases become activated through the forma-
tion of symmetric ‘‘side-to-side’’ dimers in which one RAF mole-
cule allosterically activates the other in a manner independent
from catalytic activity (Figure 2A). The activating effect of muta-
tions and inhibitors is a result of inducing a conformational
change that renders the inactivated kinase able to allosterically
activate other RAF molecules. Through this dimeric interaction,
B-RAF was also shown to allosterically activate kinase suppres-
sor of Ras (KSR), a closely related kinase previously thought to
be a bona fide catalytically inactive pseudokinase (Brennan
et al., 2011; Hu et al., 2011).
The Janus kinase (JAK) family, which includes JAK1, JAK2,
JAK3, and TYK2, provides an example of how the interaction be-
tween two kinases can be inhibitory. JAK kinases are cyto-
plasmic receptor-associated kinases that become activated
upon binding of extracellular ligands to their cognate receptors.
Each of the JAKs possesses both a pseudokinase domain and
an active kinase domain that are adjacent to each other on one
polypeptide chain. In the absence of stimulation, the pseudoki-
nase domain interacts with and inhibits the active kinase domain
(Figure 2A). Only recently, structural studies have identified
the interaction interface between the pseudokinase and kinase
domains, revealing that many disease-related mutations that
activate JAK kinases map to this interface (Lupardus et al.,
2014; Shan et al., 2014). Other recent studies suggest that the
inhibitory pseudokinase/kinase interaction might be occurring
in trans between two different JAK kinases that pre-associate
with the receptor in the absence of an activating ligand (Brooks
et al., 2014; Varghese et al., 2014). This interaction could
contribute to stabilization of an inactive receptor complex,
underscoring the multilayered role of JAK kinase domain-medi-
ated interactions in receptor activation.
Allosteric Regulation of Other Enzymes
This ability of kinases to act as allosteric regulators of signaling
also extends to modulation of the activity of unrelated enzymes
(Figure 2B). The MAPK extracellular-regulated kinase 2 (ERK2),
for instance, regulates several different enzymes through allo-
stery. ERK2 plays a critical role in regulation of the activity of
the dual-specificity phosphatase MKP3 (DUSP6), which in-
activates ERK2 by dephosphorylation. By binding directly to
MKP3, ERK2 triggers a conformational change in the MKP3 cat-
alytic domain that markedly enhancesMKP3 phosphatase activ-
ity. Active wild-type ERK2 and a kinase-dead ERK2 K52A (K72 in
PKA) mutant activate MKP3 to the same extent, suggesting that
this function of ERK2 is not dependent on kinase activity (Camps
et al., 1998). Similarly, ERK2 allosterically activates topoisomer-
ase IIa and poly(ADP-ribose) polymerase 1 (PARP1) through
mechanisms that are independent of its catalytic activity (Co-
hen-Armon et al., 2007; Shapiro et al., 1999).
Another kinase implicated in the regulation of phosphatase
activity in a phosphorylation-independent manner is vaccinia-
related kinase 3 (VRK3), a catalytically inactive pseudokinase
in the VRK family (Figure 2B). The crystal structure of VRK3
was the first structure of a pseudokinase to be solved and re-Strvealed that the putative active site of VRK3 is highly distorted
and likely incompatible with nucleotide binding. Biochemical
studies confirmed that VRK3 is indeed catalytically inactive
(Scheeff et al., 2009). Despite lacking activity, VRK3 directly
binds and stimulates the activity of vaccinia H1-related (VHR)
phosphatase, which is involved in dephosphorylation of ERK
(Kang and Kim, 2006).
Assembly of Signaling Components through Scaffolding
Scaffold proteins play critical roles in cellular signaling by binding
to multiple components within a signaling pathway and facili-
tating their interactions (Langeberg and Scott, 2015). Such
scaffolds often consist of several modular protein interaction do-
mains, such as SH2 and PDZ domains. Although singular kinase
domains lack typical characteristics of protein scaffolds, accu-
mulating evidence suggests that kinase domains can likewise
promote interactions between distinct components within
signaling pathways (Figure 2C).
Several pseudokinases have documented roles as scaffold
proteins and strictly rely on the kinase domain to perform this
function. The pseudokinases STRADa and STRADb (STE20-
related kinase adaptor) are involved in activation of liver kinase
B1 (LKB1), which in turn activates AMP-activated kinase
(AMPK) to inhibit cell proliferation when cellular ATP levels are
low. LKB1 needs to bind to the adaptor protein Mo25 to be
activated, and STRAD pseudokinases serve as scaffolds that
facilitate this interaction (Baas et al., 2003; Boudeau et al.,
2003). In this complex, both STRAD and Mo25 cooperate to sta-
bilize the active conformation of LKB1 and stimulate its catalytic
activity (Zeqiraj et al., 2009a; 2009b). STRAD therefore not only
acts as a passive scaffold, but also plays an active role in allo-
steric regulation of the scaffolded components.
The well-studied scaffold KSR plays a critical role in regulating
the Ras/MAPK pathway by coordinating assembly of the RAF/
MEK/ERK signaling module (Kolch, 2005). These functions are
dependent on the kinase domain of KSR, but not on its catalytic
activity. In response to growth factor stimulation, KSR localizes
to the plasma membrane and interacts with MEK and RAF to
promote MEK phosphorylation. KSR also interacts with ERK,
which then phosphorylates RAF and KSR to negatively regulate
the MAPK pathway (McKay et al., 2011). Like STRADa, KSR is
not a passive scaffold but is involved in allosteric regulation of
its binding partners. KSR allosterically activates B-RAF through
a side-to-side heterodimerization mechanism similar to that
observed in heterodimers between different RAF isoforms (Hu
et al., 2013; Rajakulendran et al., 2009).
Perhaps least understood is the scaffolding role of the Tribbles
(Trb) family of pseudokinases, composed of three closely related
proteins: Trb1, Trb2, and Trb3. Genetic and biochemical studies
have suggested that Trbs exhibit a diverse range of scaffolding
functions. Like KSR, Trbs facilitate interactions between kinases
in the MAPK cascade to modulate phosphorylation of MAPKs by
interacting directly with MAPK kinases (Kiss-Toth et al., 2004;
Yokoyama et al., 2010). Trbs have also been found to regulate
proteasomal degradation by interacting with ubiquitin ligases,
includingCOP1andbTrCP, and their substrates topromote ubiq-
uitination. This function of Trbs has been documented to regulate
the stability of a number of different proteins, such as acetyl
coenzyme A carboxylase, C/EBP transcription factors, and
b-catenin (Keeshan et al., 2006; Qi et al., 2006; Xu et al., 2014).ucture 24, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 9
Table 1. Active Kinases Reported to Perform Non-catalytic Functions
Kinase Non-catalytic Function(s)
Corresponding
Residue(s) in the
Active Site of PKAa References
A-RAF, B-RAF,
C-RAF (RAF1)
RAF kinases inactivated through mutations in catalytic spines
(B-RAF A471F, C-RAF A373F) or the active site (B-RAF G466E,
G466V, G596R), or binding of an inhibitor can allosterically
activate other RAF kinases through homo- or heterodimerization
A70, G52, G186 Mooz et al. (2014)
Hu et al. (2013)
Garnett et al. (2005)
Wan et al. (2004)
ActRIIa (ACtR2) Both kinase-active and kinase-dead (K219R) variants of ActRIIa
form a functional complex with the constitutively active ALK2
Q207D mutant, which depends on dimerization with ActRIIa for
signaling
K72 Bagarova et al. (2013)
Akt1, Akt2, Akt3 Studies where Akt was inactivated by inhibitors or by active site
mutations (Akt1 K179M, Akt2 K181M, Akt2 G161V) demonstrated
that Akt kinase domain conformation but not activity controls the
ability of the adjacent PH domain to bind phosphoinositides
K72, G52 Okuzumi et al. (2009)
Vivanco et al. (2014)
AMPKa1,
AMPKa2
Kinase-active and kinase-dead (AMPKa1 T172A, AMPKa2
D139A, AMPKa2 D157A) variants of AMPK interact with and
co-activate PPARa
T179, D166, D184 Bronner et al. (2004)
Aurora A The ability of Aurora A kinase to prevent N-Myc degradation
through interactions with N-Myc and SCFFbxw7 is maintained
even in the presence of type I Aurora A inhibitors
NA Otto et al. (2009)
Aurora C Both kinase-active and kinase-dead (T202D) variants of Aurora C
promote degradation of Aurora B and interfere with the spindle
assembly checkpoint
T172 Lin et al. (2014)
BMPR2 Both kinase-active and kinase-dead (K230R) variants of BMPR2
form a functional complex with the constitutively active ALK2
Q207D mutant, which depends on dimerization with BMPR2
for signaling
K72 Bagarova et al. (2013)
Brk Both kinase-active and kinase-dead (K219M) variants of Brk
promote breast carcinoma cell proliferation
K72 Harvey and Crompton (2003)
c-Kit Inhibition of c-Kit kinase by a small molecule inhibitor does not
interfere with its signaling in a complex with the granulocyte-
macrophage colony-stimulating factor (GM-CSF) receptor
NA Lennartsson et al. (2004)
CDK2 Studies using an analog-sensitive CDK2 mutant defective in
binding to cyclin A and activation loop phosphorylation revealed
that kinase domain conformation and not activity regulates
activation of CDK2. Binding of small-molecule inhibitors can
rescue both deficiencies
NA Merrick et al. (2011)
CDK6 Both kinase-active and kinase-dead (K43M) variants of CDK6
promote transcription of p16INK4a and VEGF-A
K72 Kollmann et al. (2013)
CDK9 Both kinase-active and kinase-dead (D167N) variants of CDK9
inhibit glucocorticoid receptor-mediated gene induction and
transactivation activity of B-Myb
D184 Zhu et al. (2014)
De Falco et al. (2000)
CHK (CTK) CHK binds to and inhibits Src family kinases in a phosphorylation-
independent manner
NA Chong et al. (2004)
DYRK2 Both kinase-active and kinase-dead variants of DYRK2 are
capable of interacting with EDD ubiquitin ligase and substrate
adaptors DDB1 and VPRBP to assemble the EDVP ubiquitin
ligase complex
Mutation not
specified in
the original study
Maddika and Chen (2009)
EGFR
HER2
HER4
Catalytically inactive (EGFR D813N, HER4 D843N) HER kinases
can allosterically activate other HER kinases through asymmetric
dimerization of kinase domains
D166 Zhang et al. (2006)
Monsey et al. (2010)
Qiu et al. (2008)
EphA4 Expression of kinase-dead EphA4 (K653M) is sufficient for proper
formation of anterior commissure (AC) in mice, whereas mice that
are EphA4 null exhibit defects in AC formation
K72 Kullander et al. (2001)
EphA8 Kinase-dead EphA8 (K666M, K666R) promotes cell attachment to
fibronectin as well as the wild-type EphA8
K72 Gu and Park (2001)
(Continued on next page)
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Table 1. Continued
Kinase Non-catalytic Function(s)
Corresponding
Residue(s) in the
Active Site of PKAa References
EphB3 Both kinase-active and kinase-dead (K665R) EphB3 inhibit
cell migration
K72 Miao et al. (2005)
ERK1 ERK1 is hypothesized to behave similarly to ERK2 in
displacement of retinoblastoma (Rb) protein from lamin A
NA Rodriguez et al. (2010)
ERK2 Both kinase-active and kinase-dead (K54A, K54R) ERK2
are capable of: (1) displacing retinoblastoma (Rb) protein from
lamin A; (2) allosterically activating MKP3, PARP-1, and
topoisomerase IIa; and (3) repressing transcription of interferon-
induced genes by binding directly to promoters
K72 Rodriguez et al. (2010)
Camps et al. (1998)
Cohen-Armon et al. (2007)
Hu et al. (2009)
Shapiro et al. (1999)
FAK Kinase-dead FAK (K454R) is sufficient to promote endothelial
cell survival by regulating p21 expression; both kinase-active
and kinase-dead FAK recruit paxillin to the plasma membrane
to stimulate JNK2
K72 Zhao et al. (2010)
Igishi et al. (1999)
FGFR3 Both kinase-active and kinase-dead (K508M) FGFR3 promote
degradation of BMPR1a and BMPR1b by enhancing their
association with Smurf1
K72 Qi et al. (2014)
Fyn Knockdown but not small-molecule inhibition of Fyn kinase
significantly decreases late-stage T-cell adhesion
NA Chapman et al. (2012)
GRK2 Both kinase-active and kinase-dead (K220R) GRK2 suppress
endothelin receptor signaling
K72 Freedman et al. (1997)
IGF1R IGF1R promotes phosphorylation of ERK1/2 and p38 even
when its kinase is inactivated with a small-molecule inhibitor or
through a kinase-inactivating mutation (Y1131F/Y1135F/Y1136F)
T172 Perrault et al. (2011)
IKKa Both kinase-active and kinase-dead (K44M) IKKa are capable of
inducing keratinocyte differentiation
K72 Hu et al. (2001)
IKKb Both kinase-active and kinase-dead (K44A) IKKb promote
activation of Akt and localization of Akt to the membrane
K72 Ashida et al. (2011)
INSR Both kinase-active and kinase-dead (K1030R) Insulin Receptor
(INSR) induce apoptosis in the absence of ligand and activate the
phosphatase PHLPP1 in response to insulin
K72 Boucher et al. (2010)
Zhang and Riedel (2009)
Ire1 Binding of ADP or type I inhibitors to the Ire1 kinase domain is
sufficient to promote oligomerization and activation of the RNase
domain
NA Papa et al. (2003)
Lck Studies using Lck mutants known to adopt different
conformational states were used to demonstrate that the
conformation of Lck and not its activity regulates Lck clustering
in early T-cell signaling
K72 Rossy et al. (2012)
LRRK2 Mice deficient in LRRK2, but not mice expressing kinase-dead
LRRK2 (D1994S), develop early-onset pathophysiological
changes in the lung
D166 Herzig et al. (2011)
Lyn Both kinase-active and kinase-dead (K275L) Lyn inhibit
BCR-mediated activation of PKC
K72 Katsuta et al. (1998)
MARK2 Expression of kinase-dead (T208A/S212A) MARK2 is sufficient
to rescue the multipolar to bipolar transition in neurons in which
MARK2 has been knocked out
T172 Sapir et al. (2008)
MSK2 Both kinase-active and kinase-dead (D179A/D551A) MSK2
interact with and stimulate autophosphorylation of PKR; it remains
unclear whether one or both kinase domains ofMSK2 are involved
in this interaction
D184 Kang and Ahn (2011)
MST1 Both kinase-active and kinase-dead (K59R, T183A) MST1 bind
to and inhibit androgen receptor
K72, T172 Cinar et al. (2011)
mTOR Both kinase-active and kinase-dead (D2357E) rapamycin-
resistant mTOR variants rescue myogenesis in C2C12 cells
treated with rapamycin
D184 Erbay and Chen (2001)
(Continued on next page)
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Table 1. Continued
Kinase Non-catalytic Function(s)
Corresponding
Residue(s) in the
Active Site of PKAa References
p38a Knockdown of p38a blocks cell proliferation, whereas inhibition
with small molecules has no effect on the role of p38a in cell cycle
progression
NA Fan et al. (2005)
PAK1 Both kinase-active and kinase-dead (K298R) PAK1 bind to Akt
and PDK1 to promote recruitment of Akt to the membrane and
phosphorylation of Akt by PDK1
K72 Higuchi et al. (2008)
PAK2 Both kinase-active and kinase-dead (K278R) PAK2 interact with
bpix to regulate spindle orientation
K72 Mitsushima et al. (2009)
PAK4 Both kinase-active and kinase-dead (K350M) PAK4 inhibit tumor
necrosis factor a-induced apoptosis
K72 Gnesutta and Minden (2003)
PERK Catalytically inactivated PERK (through binding of an inhibitor) can
allosterically activate another PERK kinase through dimerization
NA Dey et al. (2014)
Mendez et al. (2015)
PKR Dimerization of the PKR kinase domain seems sufficient to
allosterically active PKR kinase activity as observed for RAF
and PERK kinases
NA Dey et al. (2014)
Pyk2 Knockdown but not inhibition of Fyn kinase with a small molecule
significantly decreases late-stage T-cell adhesion
NA Chapman et al. (2012)
RIPK1 RIPK1-deficient mice die shortly after birth due to extensive
apoptosis, whereas mice expressing a kinase-dead RIPK1 K45A
or D138N mutant are viable
K72, D166 Berger et al. (2014)
Newton et al. (2014)
RIPK3 Mice lacking RIPK3 or expressing a kinase-dead RIPK3 K51A
mutant are healthy, but inactivation of RIPK3 through a kinase-
dead D161N mutation is lethal. The D161N mutation or inhibition
with small molecules enhances the ability of RIPK3 to assemble
an apoptosis-inducing complex
K72, D166 Mandal et al. (2014)
Newton et al. (2014)
TAK1 Both kinase-active and kinase-dead (K63W) TAK1 are capable
of acting as adaptors for ubiquitin ligases to promote degradation
of Bcl10
K72 Moreno-Garcı´a et al. (2013)
TrkA Both kinase-active and kinase-dead (K538A) TrkA promote
neuronal cell death
K72 Nikoletopoulou et al. (2010)
TGFbRI A kinase-dead (G217E, K232R) mutant of TGFbRI can
complement an activation-defective mutant (G261E, G322D)
to form a functional signaling complex
K72 Weis-Garcia and Massague´ (1996)
WNK2 Both kinase-active and kinase-dead (K207A, S352A/S356A)
WNK2 inhibit growth of glioma cells
K72, T172 Hong et al. (2007)
ZAP70 Inactivation of ZAP70 with a small-molecule inhibitor has no effect
on its ability to activate Rap1 GTPase
NA Au-Yeung et al. (2010)
aIndicates the residues in the active site of protein kinase A (PKA) that correspond to those mutated to generate kinase-dead alleles for cases where
kinase-inactivating mutations were used to identify non-catalytic functions.
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tions of Trb pseudokinases is poorly understood. Recently, crys-
tal structures of the Trb1 pseudokinase domain revealed that the
putative active site of Trb1 deviates markedly from that of ca-
nonical active kinases and is incompatible with ATP binding or
catalysis (Murphy et al., 2015). The structures suggest that the
interaction between the C-terminal tail of Trb1 and its pseudoki-
nase domain regulates its ability to recruit COP1.
Like pseudokinases, catalytically active kinases can also act
as scaffolds independently of their catalytic activity. The bifunc-
tional enzyme Ire1 possesses a kinase domain fused C-termi-
nally to an RNase domain and utilizes its kinase domain as a
scaffold to mediate oligomerization and activation of the RNase
domain. This results in cleavage of the HAC/XBP1 mRNA to12 Structure 24, January 5, 2016 ª2016 Elsevier Ltd All rights reservestimulate the unfolded protein response activated by ER stress.
The ability of Ire1 to oligomerize and subsequently activate the
RNase domain is regulated through a conformational change in
the kinase domain and not directly by kinase activation (Kore-
nnykh et al., 2009; Papa et al., 2003). Another related enzyme,
RNase L, is also composed of a kinase domain C-terminally
fused to an RNase domain and uses an oligomerization mecha-
nism analogous to Ire1 for RNase activation. In contrast to Ire1,
the kinase of RNase L was found to be a catalytically inactive
pseudokinase, underscoring that RNase activation can be
achieved even in the absence of kinase catalytic activity (Dong
and Silverman, 1999; Han et al., 2014; Huang et al., 2014).
RIPK1 and RIPK3 (receptor-interacting protein kinases 1 and
3) are critical regulators of inflammation and cell death thatd
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Figure 2. Non-catalytic Functions of Protein
Kinases
(A) Dimerization-induced conformational changes
distal to the active site result in activation of HER
and RAF family kinases. In JAK kinases, where
both kinase domains are located on the same
polypeptide chain, the N-terminal pseudokinase
domain inhibits the adjacent kinase domain.
(B) ERK2 allosterically activates diverse enzymes,
including MAP kinase phosphatase 3 (MKP3),
topoisomerase IIa (TOPO IIa), and poly(ADP-ribose)
polymerase 1 (PARP1), through unknown mecha-
nisms. VRK3 allosterically activates vaccinia H1-
related (VHR) phosphatase.
(C) STRAD interacts with Mo25 to activate LKB1.
KSR activates B-RAF through dimerization (1) and
brings it to MEK (2). Tribbles and DYRK2 are
thought to form complexes with ubiquitin ligases to
promote ubiquitination. RIPK3 recruits RIPK1,
Casp8, FADD, and cFLIP to form a complex that
induces apoptosis. Ire1 and RNase L use their ki-
nase domains as scaffolds for oligomerization to
activate their adjacent RNase domains.
(D) CDK6 interacts with transcription factors to
promote transcription of their targets. ERK2 binds
directly to promoter sequences to repress tran-
scription.
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Reviewhave scaffolding roles in apoptosis independent of their catalytic
activity. Genetic and biochemical studies have revealed very
distinct properties of these kinases. While knockout of RIPK1
in mice is lethal due to extensive apoptosis in several tissues
(Kelliher et al., 1998), mice that express kinase-dead RIPK1
K45A (K72 in PKA) or D138N (D166 in PKA) mutants are viable
and mature normally into adults, suggesting that non-catalytic
functions of RIPK1 are required for survival (Berger et al., 2014;
Newton et al., 2014). In contrast, RIPK3-deficient mice are
healthy, but expression of kinase-dead RIPK3 mutants has dif-
ferential effects depending on the mutation used to inactivate
the kinase. While mice expressing catalytically inactive RIPK3
K51A (K72 in PKA) are viable, expression of RIPK3 D161N
(D166 in PKA) is lethal through promotion of caspase 8-depen-
dent apoptosis (Mandal et al., 2014). The D161N mutation likely
augments the ability of RIPK3 to recruit apoptotic regulators,
including cFLIPL, FADD, and Casp8, to form an apoptosis-
inducing complex and demonstrates that this scaffolding func-
tion of RIPK3 does not depend on its catalytic activity (Mandal
et al., 2014). The discrepancies between the effects of the
K51A and D161N mutations suggest that a specific conforma-
tion of the kinase domain, favored by the D161N mutant, rather
than loss of catalytic activity, is responsible for promoting this
scaffolding function of RIPK3 in apoptosis.
DYRK2 (dual-specificity tyrosine phosphorylation-regulated
kinase 2) utilizes both catalytic and non-catalytic functions to
regulate ubiquitination. DYRK2 is required for assembly of the
complex between the EDD ubiquitin ligase and the adaptor pro-Structure 24, January 5, 201teins DDB1 and VPRBP, which together
form the EDVP complex to mediate ubiq-
uitination of substrates such as katanin
p60. While DYRK2 kinase activity is
required for the phosphorylation and sub-
sequent degradation of katanin p60, it is
dispensable for forming the EDVP com-plex (Maddika and Chen, 2009). DDB1 and VPRBP also serve
as components of a different ubiquitin ligase complex, Cul4-
Roc1, where the cullin Cul4, instead of DYRK2,mediates interac-
tions between DDB1-VPRBP and the ubiquitin ligase Roc1.
Although the structural basis for the role of DYRK2 in the forma-
tion of the EDVP complex remains unknown, it is intriguing to
speculate that DYRK2 and Cul4 might act in an analogous
manner in assembling E3 ligases with other components of ubiq-
uitination complexes.
Regulation of Transcription
Although the repertoire of non-catalytic kinase functions spans
many diverse processes, their involvement in regulation of tran-
scription, though less well understood, is worthwhile highlighting
(Figure 2D). Kinases, such as CDK6 and CDK9, have been found
to regulate transcription by interacting with transcription factors
like STAT3, c-Jun, and B-Myb in a manner that does not depend
on catalytic activity (De Falco et al., 2000; Kollmann et al., 2013).
A recent study profiling interactions between human proteins
and DNA revealed that another group of kinases, including
ERK2, RIPK3, and MAP4K2, appear to regulate transcription
by binding directly to DNA (Hu et al., 2009). In the case of
ERK2, a cluster of positively charged residues in the C lobe of
the kinase domain mediates ERK2 interactions with the pro-
moters of several genes to repress transcription. A kinase-inac-
tivating K54R (K72 in PKA) mutation and chemical inhibition had
no effect on the inhibitory role of ERK2 in transcription, indicating
that this function is independent of kinase activity (Hu et al.,
2009).6 ª2016 Elsevier Ltd All rights reserved 13
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Figure 3. Conformational Transitions
Linked to Kinase Catalysis
(A) Cartoon representation and crystal structure
(PDB: 1ATP) of the active conformation of protein
kinase A (PKA). The inset displays a close-up view
of the active site, highlighting structural elements
that are critical for catalysis.
(B) Cartoon representations (top) and crystal
structures (bottom) illustrating the structural
changes that occur as the c-Abl kinase domain
transitions between different conformational
states.
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Review‘‘Repurposing’’ the Kinase Domain for Non-catalytic
Functions
The strategic placement of kinases in critical cellular signaling
networks likely explains why they evolved to carry not one but
several alternative functions. However, the versatility with which
the kinase domain can be used to support so many unrelated
functions in a cell poses an obvious structural puzzle. How
does the primary—or so we think—function of kinases to cata-
lyze phosphorylation co-exist with these alternative roles, and
what physical features of the kinase have evolved the capability
to serve these new functions?
Structural Transitions Underlying Catalytic Function of
Kinases
Kinases exhibit a highly conserved fold with the active site
located between two lobes, the N- and C-lobes, connected via
the hinge region (Figure 3A). The motion of the hinge determines
the relative orientation of the N- and C-lobes during the catalytic
cycle. To conduct catalysis, kinases need to be dynamic to allow
nucleotide binding, hydrolysis, and release in a sequential
fashion, as well as binding and release of their substrates.
A set of defined conformational transitions accompanies these
steps and has been well characterized through decades of14 Structure 24, January 5, 2016 ª2016 Elsevier Ltd All rights reservedinsightful structural and biophysical
studies (Huse and Kuriyan, 2002; Taylor
and Kornev, 2011).
In contrast to the N-lobe, which is
composed primarily of b strands and un-
dergoes significant structural rearrange-
ments during catalysis, the C lobe, which
consists mostly of a helices, is more rigid
and possesses less conformational flexi-
bility except for one conserved structural
element called the activation loop. The
activation loop starts with a highly
conserved Asp-Phe-Gly (DFG) motif and
extends to include one or more regulatory
phosphorylation sites present in the
majority of kinases. The activation loop
undergoes significant conformational
changes during catalysis that are inti-
mately tied to kinase activation. In most
kinases, once phosphorylated, the acti-
vation loop adopts a fully extended
conformation that stabilizes the active
state of the enzyme and is important for
binding substrates. In this conformation,the DFG aspartate points into the active site to coordinate
Mg2+-ATP, while the adjacent phenylalanine points away from
the catalytic cleft (Figure 3B). This position of the DFG motif is
referred to as the ‘‘DFG-in’’ state. The aspartate and phenylala-
nine can exchange positions (‘‘DFG-out’’), positioning the bulky
phenylalanine side chain to prevent binding of the nucleotide
to the active site. This DFG-out state locks the kinase in the inac-
tive conformation and is often accompanied by significant
changes in the conformation of the activation loop (Figure 3B).
Conformational changes of the activation loop are tightly
coupled to the movements of helix aC, a conserved structural
element located in the N-lobe. In the active conformation, helix
aC is rotated toward the active site, allowing a conserved lysine
residue in the b3 strand within the N-lobe to form a salt bridge
with a conserved glutamate in helix aC (Figure 3A). Helix aC
also plays a critical role in stabilization of an inactive conforma-
tion of the kinase domain termed the Src/CDK-like inactive
conformation, which is distinct from the DFG-out inactive
conformation (Figure 3B). This conformation was first observed
in structures of cyclin-dependent kinases (CDKs) and Src family
kinases, and subsequently in several other unrelated protein ki-
nases, pointing to its potentially important role in the kinase
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Figure 4. Significance of Kinase
Conformation for Non-catalytic Functions
(A) Active conformation of the Ire1 kinase domain
induces formation of a back-to-back dimer and
higher-order oligomers of Ire1 kinase domains that
activate the adjacent RNase domain (PDB: 3FBV).
(B) Structures of mouse MLKL pseudokinase (PDB:
4M68) (left) show its activation loop in an unusual
conformation, which is hypothesized to rearrange
upon RIPK3-dependent phosphorylation, triggering
MLKL oligomerization and necroptosis. In contrast,
structures of human MLKL (PDB: 4M67) (right) show
the activation loop adopting an extended confor-
mation, possibly the conformation that results from
RIPK3-dependent phosphorylation.
(C) The active conformation of the RAF kinase
domain is required to transactivate a dimerization
partner in a side-to-side dimer (PDB: 1UWH).
(D) Mo25 stabilizes STRADa pseudokinase in an
‘‘active’’ DFG-in conformation, which is necessary
for LKB1 activation (PDB: 2WTK).
(E) Structures of the pseudokinase Trb1 reveal a non-
canonical conformation of helix aC that creates a
binding site for the C-terminal tail of Trb1 (PDB:
5CEM).
(F) In crystal structures of HER kinase asymmetric
dimers (EGFR/EGFR PDB: 2GS6, HER3/EGFR PDB:
4RIW), the conformation of the allosteric activator
kinase (active or Src/CDK-like inactive conformation)
does not seem to matter for activation of the receiver
kinase.
(G) No conformational changes in the T. gondii
pseudokinase ROP5B have been implicated in
regulation of the human GTPase IRGa6 (PDB: 4LV5).
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Reviewcatalytic cycle (Jura et al., 2011). In the Src/CDK-like inactive
state, helix aC is rotated away from the active site such that
the glutamate residue in this helix can no longer interact with
the b3 lysine. The DFG motif adopts a DFG-in conformation,
but the remainder of the activation loop folds into a short helix
rather than adopting the extended conformation seen in the
active state.
The Relevance of Conformational Changes in Kinases
for Their Non-catalytic Functions
While the structural steps of kinase-mediatedcatalysis havebeen
studied extensively, the structural underpinnings of non-catalytic
kinase functions are poorly understood. Much of the pioneering
work on this aspect of kinase signaling suggests that the struc-Structure 24, January 5, 20tural transitions associated with the kinase
catalytic cycle are indeed also supporting
thenon-catalytic functionsof kinases.Since
the three structurally well-characterized ki-
nase conformations (the active state, the
inactive DFG-out state, and the Src/CDK-
like inactive state) are associated with
significant changes on the kinase domain
surface (Figure 3B), it is plausible that non-
catalytic functions of kinases that rely on
protein-protein interaction interfaces could
be regulated by these conformational
changes.
Activation Loop Conformation and the
DFG-Out State. In several kinases, the
conformation of the activation loop is
coupled to their ability to act as allostericregulators or as scaffolds. In the case of Ire1, crystal structures
revealed that the Ire1 kinase domain dimerizes in a ‘‘back-to-
back’’ orientation in which the kinases adopt an active confor-
mation (Korennykh et al., 2009; Lee et al., 2008) (Figure 4A).
Ire1 dimerization and subsequent oligomerization of the back-
to-back dimers are critical for activation of the adjacent RNase
domain. These findings show that, even though it is possible to
activate the RNase function of Ire1 in the absence of Ire1 kinase
catalytic activity, this scaffolding function of Ire1 requires that the
kinase adopt an active conformation. Similarly, although the
pseudokinase domain of RNase L is catalytically inactive, its
RNase activity also seems to rely on the active, DFG-in, confor-
mation of the kinase domain to form a back-to-back dimer16 ª2016 Elsevier Ltd All rights reserved 15
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Reviewreminiscent of that observed for Ire1 (Han et al., 2014; Huang
et al., 2014).
The mixed lineage kinase domain-like (MLKL) pseudokinase
provides a striking example of how the activation loop can adopt
a non-canonical conformation to regulate non-catalytic functions
of a kinase. Crystal structures of theMLKL pseudokinase domain
reveal an unusual conformation in which a portion of the activa-
tion loop forms a helix, which takes the position normally occu-
pied by helix aC (Murphy et al., 2013a; Xie et al., 2013)
(Figure 4B). A glutamine residue,Q343, in the activation loop helix
of MLKL forms a hydrogen bond with the b3 lysine K219 (K72 in
PKA), mimicking the salt bridge formed between the b3 lysine
and the aC helix glutamate in the active conformation of conven-
tional kinases. Mutations, such as K219M and Q343A, that
disrupt this non-canonical interaction result in constitutive activa-
tion of necroptosis byMLKL, suggesting that the unusual confor-
mation of its activation loop represents an autoinhibited state of
MLKL and that MLKL activation relies on a conformational
change of the activation loop to release this inhibition (Murphy
et al., 2013a).
Helix aC Conformation and the Src/CDK-like Inactive State. A
significant change in the position of helix aC relative to the active
site, as well as associated changes in the conformation of the
activation loop, are hallmarks of the inactive, Src/CDK-like,
conformation (Figure 3B). The non-catalytic functions of several
kinases might be controlled by cycling between the active and
Src/CDK-like inactive state. In the case of RAF kinases, only
the active kinase conformation is compatible with allosteric
transactivation of kinases in RAF dimers (Figure 4C). Hence, in-
hibitors of B-RAF that stabilize the active state of the kinase
domain promote formation of B-RAF/C-RAF dimers, in which
the inhibitor-bound B-RAF allosterically activates C-RAF (Hatzi-
vassiliou et al., 2010). Similarly, mutations in B-RAF, C-RAF, and
KSR that stabilize the active state of the kinase domain also pro-
mote dimerization (Hu et al., 2011). In contrast, inhibitors like
vemurafenib that favor a Src/CDK-like inactive conformation of
B-RAF fail to promote B-RAF/C-RAF heterodimerization (Hatzi-
vassiliou et al., 2010; Thevakumaran et al., 2015).
The Src/CDK-like inactive conformation might also play a key
role in the function of the pseudokinase STRADa. Even though
STRADa lacks catalytic activity, the crystal structure of the
STRADa-Mo25-LKB1 ternary complex reveals that STRADa
adopts a conformation resembling the active conformation
of catalytically active kinases (Zeqiraj et al., 2009a, 2009b)
(Figure 4D). In the structure, the ‘‘active’’ conformation of
STRADa is stabilized through binding of Mo25 to the aC helix of
STRADa. This interaction is reminiscent of the mechanism by
which cyclin binding stabilizes the active conformation of CDKs
and asymmetric dimerization of HER kinases activates one of
the kinases in the asymmetric dimer. In both CDK and HER ki-
nases, disruption of these interactions promotes adoption of
the Src/CDK-like inactive conformation and kinase inactivation.
Although it is not known whether mutation of the STRADa/
Mo25 binding interface, which abrogates STRADa-mediated
activation of LKB1, shifts STRADa into the Src/CDK-like inactive
conformation, one could speculate that, like CDK and EGFR,
STRADa resides in this conformation when not bound to Mo25.
The aC helix of the pseudokinase Trb1 adopts an unusual
conformation, in which the aC helix is truncated and bent rela-16 Structure 24, January 5, 2016 ª2016 Elsevier Ltd All rights reservetive to that of conventional active kinases (Figure 4E). Intrigu-
ingly, this distorted conformation of helix aC appears to be
important for regulating Trb1 function by creating a docking
site for the C-terminal tail of Trb1 and thereby sequestering a
motif required for Trb pseudokinases to recruit the ubiquitin
ligase COP1 (Murphy et al., 2015). This example, along with
that of the non-canonical activation loop of MLKL, illustrates
how conserved kinase structural elements can be adapted
and repurposed by pseudokinases to regulate non-catalytic
functions.
Cases in which There Is No Apparent Conformational Change.
In several kinases, no conformational transitions regulating their
non-enzymatic functions have been observed. In these cases,
relatively rigid segments of the C-lobe are primarily responsible
for those non-catalytic functions. An example of this type of
non-catalytic kinase signaling is the activation of HER receptors
through formation of an asymmetric kinase dimer. In this dimer, a
hydrophobic surface on the C-lobe of one kinase is essential for
binding and allosteric activation of another kinase in the dimer
(Figure 4F). The C-lobe-localized interaction interface remains
the same in crystal structures of HER kinases regardless of the
overall conformation adopted by the allosteric activator kinase
(Aertgeerts et al., 2011; Brewer et al., 2009; Littlefield et al.,
2014; Qiu et al., 2008; Stamos et al., 2002) (Figure 4F). It remains
possible that the C-lobe interface is subject to some degree of
conformational control and that non-static biophysical ap-
proaches that inform on dynamic properties of proteins are
necessary to capture these transitions.
If the allosteric interface in HER kinases is indeed independent
of conformational changes within the kinase domain, how is the
allosteric activator function of these kinases regulated? One po-
tential mechanism by which HER activation could be regulated is
through occlusion of the hydrophobic C-lobe interface by bind-
ing of other proteins or through intramolecular interactions with
adjacent domains. The former of these mechanisms has been
described for EGFR and relies on the function of the inhibitory
protein, MIG6 (Zhang et al., 2007). The MIG6-binding site
on EGFR overlaps with the allosteric activator interface on the
C-lobe of EGFR, and MIG6 was shown to block formation of
the asymmetric EGFR kinase dimer.
Like the HER receptors, there is no evidence of conforma-
tional changes playing a role in the inhibition of the human
GTPase IRGa6 by the Toxoplasma gondii pseudokinase
ROP5B. ROP5B stabilizes the inactive form of IRGa6 by inter-
acting with it through the C-lobe of the kinase domain
(Figure 4G) (Fleckenstein et al., 2012; Reese et al., 2014). The
conformation of the pseudokinase domain in the ROP5B/
IRGa6 structure is nearly identical to that observed in structures
of apo ROP5B and ATP-bound ROP5B, suggesting that the
pseudokinase domain does not need to undergo significant
conformational changes to engage with IRGa6 (Reese and
Boothroyd, 2011; Reese et al., 2014). It is therefore likely that
interaction of ROP5B with IRGa6 is regulated through a
different mechanism. As with the HER kinases, a potential
mode of regulation could be occlusion of the IRGa6-binding
site on ROP5B by other proteins. Since ROP5B binds to the
GDP-bound, inactive form of IRGa6, it is also possible that
the nucleotide state of IRG6a regulates the strength of the
IRGa6/ROP5B interaction.d
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Figure 5. Mechanisms Regulating Kinase
Conformational Changes Involved in Non-
catalytic Functions
(A) Phosphorylation by RIPK3 induces a confor-
mational change in the activation loop of MLKL,
triggering MLKL oligomerization and necroptosis.
Phosphorylation of the N-terminal acidic (NtA)
motif in RAF kinases stabilizes their active
conformation, enabling them to allosterically acti-
vate another RAF kinase in a side-to-side dimer.
(B) Binding of ADP-Mg2+ stabilizes the active
conformation of the Ire1 kinase domain, pro-
moting oligomerization and activation of the
RNase domain. Similarly, binding of the second
messenger 2-5A and a nucleotide to the RNase
L pseudokinase domain induces dimerization and
activation of the RNase domain.
(C) STRADa requires binding of both Mo25 and
ATP to be able to allosterically activate LKB1.
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Non-catalytic Functions of Kinases
Post-translational Modifications
Kinases are frequently phosphorylated on their activation loop or
in regulatory regions outside the kinase domain. These phos-
phorylation events often induce conformational changes that un-
derlie transitions of a kinase between active and inactive states.
While we conventionally think of this type of phosphorylation as a
means to activate the catalytic activity of a kinase, it has become
apparent that phosphorylation-induced conformational changes
can also regulate the non-catalytic functions of kinases.
Phosphorylation of the activation loop usually stabilizes it in an
extended state, and this conformational change seems to be
particularly relevant for non-catalytic functions of kinases. For
example, ERK2 needs to be phosphorylated on its activation
loop by another kinase, MEK, to activate PARP1 and topoisom-
erase IIa in a catalysis-independentmanner (Cohen-Armon et al.,
2007; Shapiro et al., 1999). This suggests that the activation loop
of ERK2must adopt an extended conformation for ERK2 to func-
tion as an allosteric regulator.
Activation loop phosphorylation is also critical for triggering
oligomerization of the pseudokinase MLKL and its translocation
to the plasma membrane and intracellular membrane com-
partments to form membrane-disrupting pores, resulting in
necroptosis (Wang et al., 2014) (Figure 5A). This effect of phos-
phorylation is similar to that of previously discussed necropto-
sis-inducing mutations (K219M and Q343A) in MLKL that disrupt
the interaction between the b3 lysine and activation loop helix
glutamine (Murphy et al., 2013a;Wang et al., 2014). These obser-
vations support a model in which phosphorylation of the MLKL
activation loop byRIPK3 kinase induces a unique conformational
change in the pseudokinase domain that allows MLKL to pro-
mote necroptosis (Figure 4B).
Phosphorylation of an N-terminal acidic (NtA) motif in RAF ki-
nases is important for their allosteric activation by dimerizationStructure 24, January 5, 201(Figure 5A). NtA phosphorylation is
thought to stabilize an active conforma-
tion of RAF kinases, which is essential
for formation of active RAF dimers. In a
RAF dimer, only the kinase that is the allo-
steric activator of the other requires NtAphosphorylation. The NtA motif of B-RAF is constitutively phos-
phorylated, whichmay explain why even kinase-deadmutants of
B-RAF can activate other RAF isoforms, such as C-RAF (Hu
et al., 2013). The molecular mechanism by which NtA phosphor-
ylation stabilizes the active conformation remains to be under-
stood.
Occupancy of the Nucleotide-Binding Pocket
Binding of nucleotides and ATP-competitive inhibitors that stabi-
lize the active conformation of the Ire1 kinase domain was shown
to be sufficient to induce activation of the RNase domain through
oligomerization (Korennykh et al., 2009; Papa et al., 2003)
(Figure 5B). Small-molecule binding to the ATP pocket triggers
a conformational rearrangement of the aC helix from a position
similar to that observed in the Src/CDK-like conformation into
an active conformation that supports oligomerization of the
Ire1 kinase (Ali et al., 2011; Korennykh et al., 2011). Interestingly,
ADP or its mimic ADPbS are more potent activators of Ire1
RNase activity than ATP, because they bind preferentially to
the active conformation of the kinase domain, while ATP is
believed to bind readily even when helix aC is in an inactive po-
sition (Korennykh et al., 2011). However, ADP and ADPbS fail to
stimulate RNase activity in the absence of thiophilic metal ions
such as Mn2+ and Cd2+ that are likely necessary to properly po-
sition the b-phosphate of ADP to enable movement of helix aC
into the active position. Uncharged, synthetic ATP-competitive
small molecules can bypass the requirement for a metal cation
by inserting bulky moieties into the b-phosphate position (Kore-
nnykh et al., 2011).
The role of nucleotide binding in activation of the RNase
domain of RNase L is slightly different (Figure 5B). In contrast
to Ire1, the first step of RNase L oligomerization is regulated by
a second messenger 2-5A (20,5’-oligoadenylate), which binds
to a pocket formed by the ankyrin repeat and pseudokinase do-
mains of RNase L. Binding of 2-5A is sufficient to induce dimer-
ization of the pseudokinase domain even in the absence of6 ª2016 Elsevier Ltd All rights reserved 17
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Reviewnucleotide, but insufficient for activating the RNase domain, for
which nucleotide binding to the pseudokinase domain is
required (Dong and Silverman, 1999; Huang et al., 2014). Unlike
Ire1, RNase L is activated equally well by ADP, ATP, and the non-
hydrolyzable ATP analog AMP-PNP. In existing crystal struc-
tures, the pseudokinase domain of RNase L adopts a DFG-in
conformation resembling the active conformation of canonical
kinases regardless of the nucleotide-bound state, making the
role of nucleotide binding unclear (Han et al., 2014; Huang
et al., 2014).
Protein-Protein Interactions
The ability of the pseudokinase STRADa to allosterically acti-
vate LKB1 is regulated by both nucleotide binding and interac-
tion with a protein partner, Mo25. STRADa requires binding of
both ATP and Mo25 to activate LKB1 (Baas et al., 2003; Bou-
deau et al., 2003; Zeqiraj et al., 2009b) (Figure 5C). Interaction
with Mo25 enhances the ability of STRADa to bind ATP. Simi-
larly, ATP increases the affinity of STRADa for Mo25, likely by
stabilizing the conformation of STRADa that is recognized by
Mo25.
Exploiting the Dynamic Nature of the Kinase Domain to
Regulate Non-catalytic Functions of Protein Kinases
The remarkable progress in kinase inhibitor discovery over
recent years has led to the development of numerous small mol-
ecules targeting kinases, the majority of which compete with
ATP for binding to the nucleotide-binding site. In addition to their
task of blocking ATP binding, these inhibitors also tend to pref-
erentially stabilize kinases in different conformational states.
Most of these ATP-competitive inhibitors bind to the active
DFG-in conformation of the kinase domain and have been
termed type I inhibitors. In contrast, type II kinase inhibitors are
also ATP-competitive, but selectively bind to the inactive DFG-
out conformation. As it turns out, this conformational selection
makes some inhibitors potent regulators of the non-catalytic
functions of their target kinases.
Serendipitous Discoveries of Small Molecules that
Modulate Non-catalytic Functions of Kinases
It was quite puzzling that several Type I B-RAF inhibitors, such as
GDC-0879, were observed to paradoxically activate MAPK
signaling in cells despite potently inhibiting B-RAF kinase activity
in vitro. We now know that their potential to stabilize the active
kinase conformation allows these inhibitors to activate signaling
at subsaturating concentrations where inhibitor-bound RAF
molecules can dimerize with and allosterically activate apo
RAF molecules, resulting in activation of downstream signaling
(Hatzivassiliou et al., 2010; McKay et al., 2011; Poulikakos
et al., 2010) (Figure 6A). In contrast, inhibitors such as vemurafe-
nib, which stabilizes the Src/CDK-like inactive conformation of
RAF (Thevakumaran et al., 2015; Wenglowsky et al., 2011), fail
to promote kinase dimerization (Hatzivassiliou et al., 2010)
(Figure 6B). Surprisingly, despite this, vemurafenib does induce
paradoxical activation of MAPK signaling in cells expressing
wild-type B-RAF. The mechanism underlying this remains poorly
understood, but might be due to vemurafenib’s ability to disrupt
interaction of B-RAF with inactive MEK (Haling et al., 2014).
Activation of PERK (PKR-like ER kinase) by the ATP-compet-
itive inhibitor IPA appears to proceed through a mechanism
similar to that of B-RAF, in which IPA drives PERK oligomeriza-18 Structure 24, January 5, 2016 ª2016 Elsevier Ltd All rights reservetion and stimulates PERK activity at low doses by stabilizing
the active conformation of the PERK kinase domain (Mendez
et al., 2015). Likewise, the RNase activity of Ire1 can be induced
by the addition of ATP-competitive inhibitors that selectively sta-
bilize the active conformation of the Ire1 kinase domain (Kore-
nnykh et al., 2009; Wang et al., 2012). These observations
suggest that activation of the non-catalytic functions of kinases
as a result of drug-induced conformational change may be a
more widespread phenomenon associated with kinases that
are activated through oligomerization.
Another example of inhibitors that unexpectedly unveiled a
novel mode of non-catalytic kinase signaling are RIPK3-spe-
cific inhibitors, which were initially shown to block RIPK3-
dependent necroptosis when apoptosis is blocked via caspase
inhibition (Kaiser et al., 2013; Mandal et al., 2014). Surprisingly,
in the absence of caspase inhibition these inhibitors display un-
expectedly high cytotoxicity by triggering caspase activation
and apoptotic cell death by promoting RIPK3 oligomerization
and RIPK3-dependent formation of a large apoptotic signaling
complex. This outcome is reminiscent of the effect that the ki-
nase-inactivating D161N mutation has on RIPK3 signaling
(Mandal et al., 2014; Newton et al., 2014), underscoring the
innate potential of RIPK3 to promote apoptosis in an oligo-
merization-dependent manner that likely relies on a specific
conformation of the kinase domain induced by both the
D161N mutation and the inhibitors.
Successful Design of Inhibitors Targeting Non-catalytic
Functions of Protein Kinases
Since type I Ire1 kinase inhibitors that stabilize the active confor-
mation of the kinase domain result in activation of the RNase
domain, the hypothesis was proposed that type II inhibitors
that bind to the inactive DFG-out conformation would inhibit
RNase activity (Wang et al., 2012). A subset of these com-
pounds, termed KIRAs (kinase-inhibiting RNase attenuators),
was identified and predicted by molecular modeling to stabilize
the DFG-out conformation of the kinase domain (Ghosh et al.,
2014; Wang et al., 2012). Comparison of KIRAs with the type I in-
hibitor APY29 confirmed their differential effect on Ire1 oligomer-
ization and activation. Although both types of compounds inhibit
Ire1 autophosphorylation, APY29 enhances oligomerization and
stimulates RNase activity, while KIRAs disrupt oligomerization
and block RNase activity (Ghosh et al., 2014; Wang et al.,
2012) (Figures 6A and 6B).
Aurora A kinase, which is a catalytically active kinase, is
frequently overexpressed in cancers and is a target of several
ATP-competitive inhibitors. Aurora A was found to interact with
the transcription factor N-Myc and the ubiquitin ligase SCFFbxw7
to prevent N-Myc degradation in neuroblastomas whereMYCN,
the gene encoding N-Myc, is amplified (Otto et al., 2009). This
function of Aurora A is preserved in the presence of kinase-inac-
tivating mutations, such as K162R (K72 in PKA) and D274N
(D184 in PKA), as well as some ATP-competitive inhibitors,
such as hesperadin, indicating that this function does not
depend on Aurora A kinase activity (Otto et al., 2009). A different
class of ATP-competitive inhibitors has shown promise in inhib-
iting Aurora A-mediated stabilization of N-Myc and was further
developed into potent compounds, including MLN8054,
MLN8237, and CD532, that induce degradation of N-Myc by dis-
rupting the interaction between Aurora A and N-Myc (Figure 6C).d
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Figure 6. Targeting Non-catalytic Functions of Kinases with Small Molecules
(A) Examples of inhibitors that stabilize the active conformation of kinases, which in the majority of cases promote their non-catalytic functions.
(B) Examples of inhibitors that stabilize inactive conformations of kinases and their inhibitory effect on non-catalytic kinase functions.
(C) Inhibitors of Aurora A that interfere with its non-catalytic function by stabilizing a non-canonical inactive conformation.
Structure
ReviewUnlike hesperadin, these inhibitors stabilize an unusual inactive
conformation of Aurora A in which the phenylalanine of the
DFG motif is oriented such that helix aC is further away from
the active site than is typically observed in kinase structures
(Brockmann et al., 2013; Gustafson et al., 2014). The potency
of these compounds seems to be related to the degree with
which they displace helix aC (Gustafson et al., 2014). Although
these conformational transitions might represent a structural
artifact of drug binding to Aurora A, it is exciting to speculate
that they might also constitute a physiologically relevant regula-
tory step in controlling N-Myc degradation.
In an effort to use ATP-competitive small molecules to modu-
late the non-catalytic interactions ofMAP kinaseswith their bind-
ing partners, conformation-specific inhibitors that bind to the
DFG-in and DFG-out states of ERK2 were found to have distinctStrueffects on interactions of ERK2 with upstream activators (Hari et
al., 2014). While a type II inhibitor that stabilizes the DFG-
out conformation markedly reduced phosphorylation of the
activation loop of ERK2 by MEK2, type I inhibitors that
bind in a DFG-in state had only a weak effect. The type I and
type II inhibitors also had differential effects on the ability
of ERK2 to allosterically activate MKP3. The type II, DFG-out
ERK2 inhibitor decreased the rate of dephosphorylation of
ERK2 by MKP3, whereas type I DFG-in inhibitors enhanced
dephosphorylation (Figures 6A and 6B). Interestingly, the DFG-
out inhibitor blocked the ability of ERK2 to activateMKP3without
affecting their mutual binding (Hari et al., 2014). These findings
further underscore the potential for modulation of non-enzymatic
kinase functions through the design of conformation-specific
inhibitors.cture 24, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 19
Structure
ReviewThe catalytically inactive pseudokinase MLKL exemplifies
another successful effort to identify an inhibitor of a non-enzy-
matic kinase function. A screen of known kinase inhibitors iden-
tified a compound that binds to the nucleotide-binding pocket of
MLKL. This compound enhances phosphorylation of the MLKL
activation loop by RIPK3, but it prevents translocation of MLKL
to membrane compartments and therefore blocks necroptosis,
the physiological consequence of MLKL activation loop phos-
phorylation (Hildebrand et al., 2014). These findings suggest
that the compound induces only a partial conformational change
that enables activation loop phosphorylation of MLKL but not
signal propagation.
Conclusions
Structural studies of kinases have highlighted awide spectrum of
conformational states achieved by the kinase domain that can
uniquely contribute to cellular signaling independently of kinase
enzymatic activity. Interestingly, it is an active kinase con-
formation that most frequently seems to be essential for the
non-catalytic functionalities of kinases (Figure 6A). In the case
of catalytically active kinases, this conformational preference
might simply reflect the fact that catalytic and non-catalytic ki-
nase functions are coupled to the same activating input. In the
case of pseudokinases, such as RNase L, the functional impor-
tance of the active conformation is also not entirely surprising,
since the function of the RNase L pseudokinase closely mimics
the mechanism by which the catalytically active Ire1 kinase reg-
ulates activity of the adjacent RNase domain. More intriguing is
the fact that pseudokinases, such as STRADa, also rely on a
conformation resembling the active DFG-in conformation
observed for active kinases to form a functional signaling com-
plex with Mo25 and the catalytically active LKB1 kinase. This
widespread relevance of the active DFG-in conformation in regu-
lation of the non-catalytic functionsmight reflect the fact that this
conformation carries several recognizable structural features
that can easily plug into protein-protein interaction networks
trained to recognize active kinases.
Althoughmany non-catalytic functions of kinases aremisregu-
lated in disease, so far only a limited set of small molecules that
can target these functions has been discovered. The examples
discussed in this review demonstrate that it is possible to modu-
late the non-catalytic functions of both active kinases and pseu-
dokinases by leveraging our knowledge of small-molecule
design for targeting the nucleotide-binding pocket. Since many
non-catalytic functions of kinases appear to be tied to the active
DFG-in conformation of the kinase domain, inhibitors that select
for inactive conformations such as the DFG-out conformation or
Src/CDK-like conformation could be used to disrupt non-enzy-
matic functions, as demonstrated for Ire1 and ERK2. This is
also particularly important to consider in light of examples in
which kinase inhibitors can induce paradoxical activation of their
targets, as shown for B-RAF (Hatzivassiliou et al., 2010; McKay
et al., 2011; Poulikakos et al., 2010) and, more recently, PERK
(Mendez et al., 2015). At the same time, as illustrated by the
Aurora A inhibitors MLN8054, MLN8237, and CD532 (Brock-
mann et al., 2013; Gustafson et al., 2014), these small molecules
need not stabilize ‘‘native’’ conformations of the kinase domain,
but any conformation that deviates from the one relevant for
signaling.20 Structure 24, January 5, 2016 ª2016 Elsevier Ltd All rights reserveWhile progress is being made in designing ATP-competitive
inhibitors of non-catalytic kinase functions, the potential of utiliz-
ing other small molecules should not be ignored. For example,
molecules that bind to allosteric regulatory sites in kinases could
stabilize the kinase domain in unique conformational states and
be particularly useful in drugging pseudokinases, many of which
possess putative nucleotide-binding pockets that are impaired
in binding nucleotide analogs (Murphy et al., 2013b). Alterna-
tively, as recently shown for a catalytically impaired PINK1
G309D disease mutant, kinases whose active sites are poor
binders of ATP can sometimes accommodate other molecules
in their active site pockets (Hertz et al., 2013). This observation
opens up the possibility that more kinases could bind non-ca-
nonical small molecules in their active sites as a means of regu-
lating their non-catalytic functions and also shows that we
should be open-minded about therapeutic strategies aiming to
pharmacologically regulate these emerging kinase functions.
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